Acolbifene/prasterone

Acolbifene/prasterone
Combination of
AcolbifeneSelective estrogen receptor modulator
PrasteroneAndrogen
Clinical data
Trade namesFemivia (tentative)
Other namesPrasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene
Routes of
administration		By mouth

Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women. The formulation is intended for use by mouth. As of December 2017, it is in phase III clinical trials for this indication.

See also

References

  1. 1 2 3 "Acolbifene/Prasterone - Endoceutics - AdisInsight".